Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

UK says vaccine manufacturing is 'lumpy' but still on course for targets

Published 18/01/2021, 07:23
Updated 18/01/2021, 12:51
© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Lichfield

© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Lichfield

By Guy Faulconbridge and Kate Holton

LONDON (Reuters) - Britain's vaccine rollout is limited by a "lumpy" manufacturing process affecting supplies of both Pfizer (NYSE:PFE) and AstraZeneca, but is on track to hit its targets, Vaccine Deployment Minister Nadhim Zahawi said on Monday.

The United Kingdom, which has the world's fifth worst official death toll from COVID-19, is racing to be among the first major countries to vaccinate its population - seen as the best way to exit the pandemic and get the economy going again.

Britain has inoculated 3,857,266 people with a first dose and 449,736 with a second dose. On vaccines administered per 100 people, the United Kingdom is fourth in the world after Israel, the United Arab Emirates and Bahrain.

Pfizer said on Friday it would temporarily reduce its deliveries to Europe of its vaccine against coronavirus infections while it upgrades its production capacity.

"There's bound to be delays. Any new manufacturing process has challenges at the outset. It is lumpy, it begins to stabilise and get better and better week in, week out," Zahawi told the BBC, adding that Pfizer was doing "really well".

"They want to do more, which is why they're reconfiguring to add volume to the whole world...That could delay supply but I'm confident we can meet our target."

Britain aims to administer first doses of vaccine to 15 million people in the highest priority cohorts by mid-February.

Pfizer said it was coordinating with the government to "work through the short-term impact of these changes to our January deliveries".

"We understand a change to deliveries has the potential to create uncertainty," a Pfizer spokeswoman said. "However, we can confirm the overall projected volumes of delivery to the UK remain the same for quarter one (January to March)."

Zahawi told LBC radio that Britain was hoping for 2 million vaccines a week from AstraZeneca by the end of January but that those numbers would not be reached until mid February.

Last Wednesday, AstraZeneca's UK president said the firm would scale up to 2 million doses a week on or before the middle of February. A spokesman for AstraZeneca declined to comment further on Zahawi's latest guidance.

VACCINE HOPES

Mass COVID-19 vaccines are seen as the best way to exit the pandemic, which has killed more than 2 million people worldwide, wiped out trillions of dollars in economic output and upended normal life for countless people.

The United Kingdom is vaccinating 140 people per minute against COVID-19 on average.

"It is going well, we're vaccinating on average 140 people, that's first jab, literally a minute. That's the average so some areas are doing better," Zahawi told Sky.

Britain is currently rolling out the vaccine to the most vulnerable first, starting with those who are in care homes or over 80 years of age. In areas where a majority of over 80s have been offered a vaccine, letters are going out to the over 70s and those who are clinically extremely vulnerable.

Zahawi said a 24-hour vaccine offering would begin to be piloted in London by the end of the month.

Essential workers such as teachers, the police and shop assistants could move to the top of the list for a vaccine once all those over 50 have been offered a shot, Zahawi said.

© Reuters. Outbreak of the coronavirus disease (COVID-19) in London

"Teachers, police officers, shop workers, those who through no fault of their own other than the work that they do may come into contact with the virus in much greater volume, should be top of the list," Zahawi told Times Radio.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.